Is a complete ATOS research report available?

No complete published report is available for Atossa Therapeutics, Inc. (ATOS) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Atossa Therapeutics, Inc. (ATOS)

NASDAQ: ATOS · USD

$2.19

-0.12 (-5.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first ATOS analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	18.9M
Net income (ttm)	-37.6M
EPS (ttm)	-$4.37
Shares out	8.6M
Volume	32,532
Beta	1.25
Price target	$22.0	+904.6%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -37.6M
EPS (ttm): -$4.37
Market cap: 18.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All ATOS indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001488039
Company name	Atossa Therapeutics, Inc.
Country	United States
Country code	US
Cusip	04962H704
Employees	16
Employees Change	1%
Employees Change Percent	6.67
Enterprise value	$-12.6M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2012-11-08
Isin	US04962H7044
Last refreshed	2026-07-31
Market cap	$18.9M
Market cap category	Nano-Cap
Price	$2.19
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	ATOS
Website	https://www.atossatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-196.9%
FCF yield	-174.7%
P/B ratio	0.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-37.6M
Net Income Growth Years	0%
Profit Per Employee	$-2.4M
ROA	-45.54
Roa5y	-20.45
ROCE	-129.9
ROE	-78.58
Roe5y	-33.78
ROIC	-51.66

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-43.66%
Cagr1y	-84.23%
Cagr3y	-49.14%
Cagr5y	-48.17%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$37.9M
Cash	$31.7M
Current Assets	$36.7M
Current Liabilities	$7.5M
Debt	$0
Equity	$30.5M
Liabilities	$7.5M
Long Term Assets	$1.3M
Long Term Liabilities	$0
Net Cash	$31.7M
Net Cash By Market Cap	$166
Net Cash Growth	-51.29%
Net Debt Equity	$-1.04
Tangible Book Value	$30.5M
Tangible Book Value Per Share	$3.54
WACC	11.11

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.92
Net Working Capital	$-2.5M
Quick ratio	4.25
Working Capital	$29.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.82%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-99.68%
1Y total return	-84.21%
200-day SMA	7.02
3Y total return	-86.85%
50-day SMA	3.07
50-day SMA vs 200-day SMA	50under200
5Y total return	-96.26%
All Time High	33,480
All Time High Change	-99.99%
All Time High Date	2013-03-19
All Time Low	1.7
All Time Low Change	28.82%
All Time Low Date	2026-06-25
ATR	0.19
Beta	1.25
Beta1y	1.35
Beta2y	2.1
Ch YTD	-75.25
High	2.3
High52	19.35
High52 Date	2025-10-09
High52ch	-88.68%
Low	2.18
Low52	1.7
Low52 Date	2026-06-25
Low52ch	28.82%
Ma50ch	-28.62%
Price vs 200-day SMA	-68.81%
RSI	37.34
RSI Monthly	32.92
RSI Weekly	28.55
Sharpe ratio	-1.7x
Sortino ratio	-1.93
Total Return	-1.82%
Tr YTD	-75.25
Tr1m	10.61%
Tr1w	-9.13%
Tr3m	-58.52%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	0
Analyst Ratings	Buy
Earnings EPS Estimate	$-1.09
Operating Income	$-39.6M
Price target	$22
Price Target Change	$905

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8,576,595%
Float Percent	99.6%
Shares Insiders	0.4%
Shares Institutions	17.72%
Shares Out	8,611,361
Shares Qo Q	0.13%
Shares Yo Y	1.82%
Short Float	9.05%
Short Ratio	2.99
Short Shares	9.01

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-36.2M
Adjusted OCF	-36,189,000
Average Volume	106,512.35x
Bv Per Share	3.54
CAPEX	$-14,000
Ch10y	-99.68
Ch1m	10.61
Ch1w	-9.13
Ch1y	-84.21
Ch3m	-58.52
Ch3y	-86.85
Ch5y	-96.26
Ch6m	-75.67
Change	-5.19%
Change From Open	-4.37
Close	2.31
Days Gap	-0.87
Depreciation Amortization	16,000
Dollar Volume	71,245.1
Earnings Date	2026-08-13
Earnings Time	bmo
EBIT	$-39.6M
EBITDA	$-39.6M
EPS	$-4.37
F Score	1
FCF	$-33.4M
FCF EV Yield	265.05x
FCF Per Share	$-3.88
Fiscal Year End	December
Founded	2,009
Investing CF	-14,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-08
Last Report Date	2026-03-31
Last Split Date	2026-02-02
Last Split Type	Reverse
Last10k Filing Date	2026-03-25
Ma150	5.18
Ma150ch	-57.71%
Ma20	2.37
Ma20ch	-7.52%
Net CF	-33,398,000
Next Earnings Date	2026-08-11
Open	2.29
Optionable	Yes
Position In Range	8.7
Post Close	2.19
Postmarket Change Percent	-0.46
Postmarket Price	$2.18
Price Date	2026-07-30
Ptbv Ratio	0.63
Relative Volume	0.31x
Share Based Comp	2,805,000
Tr6m	-75.67%
Us State	Washington
Volume	32,532

Atossa Therapeutics, Inc. (ATOS)

Coverage state: Market snapshot only — no published research

Generate the first ATOS analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · ATOS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ATOS indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on ATOS

Frequently asked questions